Bristol-Myers Squibb (BMY) stock price, revenue, and financials

Bristol-Myers Squibb market cap is $143.9 b, and annual revenue was $42.52 b in FY 2020

$143.9 B

BMY Mkt cap, 07-May-2021

$11.1 B

Bristol-Myers Squibb Revenue Q1, 2021
Bristol-Myers Squibb Gross profit (Q1, 2021)8.2 B
Bristol-Myers Squibb Gross profit margin (Q1, 2021), %74.3%
Bristol-Myers Squibb Net income (Q1, 2021)2 B
Bristol-Myers Squibb Cash, 31-Mar-202111 B
Bristol-Myers Squibb EV179.2 B

Bristol-Myers Squibb Revenue

Bristol-Myers Squibb revenue was $42.52 b in FY, 2020

Embed Graph

Bristol-Myers Squibb Revenue Breakdown

Embed Graph

Bristol-Myers Squibb revenue breakdown by business segment: 30.3% from Eliquis, 27.6% from Opdivo, 11.4% from Orencia, 8.1% from Sprycel, 5.7% from Yervoy, 6.4% from Other Brands and 10.6% from Other

Bristol-Myers Squibb revenue breakdown by geographic segment: 58.7% from United States, 24.0% from Europe, 15.3% from Rest of World and 2.0% from Other

Bristol-Myers Squibb Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

20.8b22.6b26.1b42.5b

Revenue growth, %

7%9%16%

Cost of goods sold

6.1b6.5b8.1b11.8b

Gross profit

14.7b16.0b18.1b30.7b

Gross profit Margin, %

71%71%69%72%

R&D expense

6.4b6.3b6.1b11.1b

General and administrative expense

4.7b4.6b4.9b7.7b

Operating expense total

11.1b10.9b12.2b18.8b

Depreciation and amortization

1.1b

Pre tax profit

5.1b6.0b5.0b(6.9b)

Income tax expense

4.2b1.0b1.5b2.1b

Net Income

975.0m4.9b3.5b(9.0b)

EPS

0.63.02.0

Bristol-Myers Squibb Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

5.4b6.9b12.3b14.5b

Accounts Receivable

6.3b6.0b7.7b8.5b

Prepaid Expenses

576.0m

Inventories

1.2b1.2b4.3b2.1b

Current Assets

14.9b17.2b29.4b30.2b

PP&E

5.0b5.0b6.3b5.9b

Goodwill

6.9b6.5b22.5b20.5b

Total Assets

33.6b35.0b129.9b118.5b

Accounts Payable

2.2b1.9b2.4b2.7b

Short-term debt

987.0m1.7b3.3b2.3b

Current Liabilities

9.6b10.7b18.3b19.1b

Long-term debt

7.0b5.6b43.4b48.3b

Total Debt

8.0b7.3b46.7b50.7b

Total Liabilities

21.7b20.9b78.2b80.6b

Common Stock

221.0m221.0m292.0m292.0m

Preferred Stock

Additional Paid-in Capital

1.9b2.1b43.7b44.3b

Retained Earnings

31.2b34.1b34.5b21.3b

Total Equity

11.8b14.1b51.7b37.9b

Debt to Equity Ratio

0.7 x0.5 x0.9 x

Debt to Assets Ratio

0.2 x0.2 x0.4 x

Financial Leverage

2.8 x2.5 x2.5 x3.1 x

Bristol-Myers Squibb Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

975.0m4.9b3.5b(9.0b)

Depreciation and Amortization

789.0m637.0m1.7b10.4b

Accounts Receivable

(431.0m)(429.0m)752.0m(646.0m)

Inventories

(29.0m)(216.0m)463.0m2.7b

Accounts Payable

320.0m(59.0m)229.0m188.0m

Cash From Operating Activities

5.3b5.9b8.1b14.1b

Purchases of PP&E

(1.1b)(951.0m)(836.0m)(753.0m)

Cash From Investing Activities

(66.0m)(874.0m)(9.8b)(10.9b)

Short-term Borrowings

727.0m(543.0m)131.0m

Long-term Borrowings

(1.2b)(5.0m)(9.3b)(2.7b)

Dividends Paid

(2.6b)(2.6b)(2.7b)(4.1b)

Cash From Financing Activities

(4.1b)(3.5b)7.6b(1.2b)

Net Change in Cash

1.2b1.5b5.9b2.2b

Bristol-Myers Squibb Ratios

USDFY, 2017

Revenue/Employee

876.6k

Debt/Equity

0.7 x

Debt/Assets

0.2 x

Financial Leverage

2.8 x

Bristol-Myers Squibb Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Manufacturing Facilities

677

Phase I Trials Products (Cardiovascular)

223

Phase I Trials Products (Fibrotic Diseases)

111

Phase I Trials Products (Hematology)

14

Phase I Trials Products (Immunology)

455

Phase I Trials Products (Oncology)

211519

Phase II Trials Products (Cardiovascular)

333

Phase II Trials Products (Fibrotic Diseases)

323

Phase II Trials Products (Hematology)

8

Phase II Trials Products (Immunology)

224

Phase II Trials Products (Oncology)

6914

Phase III Trials Products (Cardiovascular)

11

Phase III Trials Products (Hematology)

10

Phase III Trials Products (Immunology)

234

Phase III Trials Products (Oncology)

789

Projects in R&D Pipeline

3244

Research and Development Centers

7712

Bristol-Myers Squibb Sustainability Metrics

 FY, 2019

Water Used Intensity

99.1 liters per 1000 USD sales

Water Used

2.59 b liters

Waste Generated

10.8 m kilograms

Total Greenhouse Gas Emissions

356 m kilogram of carbon dioxide equivalent

Total Energy Used

8 m GJ

Recordable Case Rate

0.39 cases per 100 employees

Nonhazardous Waste Generated

9.5 m kilograms

Nonhazardous Waste (Recycled)

3.7 m kilograms

Hazardous Waste Generated

1.3 m kilograms

Hazardous Waste (Recycled)

20 k kilograms

Greenhouse Gas Emissions (Scope 3, Business Travel)

55.8 m kilogram of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 2)

111 m kilogram of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1)

173 m kilogram of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1 and Scope 2)

284 m kilogram of carbon dioxide equivalent

Energy Used (Indirect)

3.5 m GJ

Energy Used (Direct)

3.3 m GJ

Energy Used (Business Air Travel)

900 k GJ

Days Away From Work Case Rate

0.13 cases per 100 employees

Bristol-Myers Squibb Employee Rating

4.12631 votes
Culture & Values
4.1
Work/Life Balance
4
Senior Management
3.6
Salary & Benefits
4
Career Opportunities
3.6
Source